Phillips-Medisize to Manufacture Wearable, Electronic-Enabled Combination Product

October 24, 2019

Phillips-Medisize, a Molex company, revealed its agreement with a biotechnology company to manufacture a wearable electronic-enabled combination product.

In an Oct. 22, 2019 press release, Phillips-Medisize, a Molex company, revealed its agreement with a biotechnology company to manufacture a wearable electronic-enabled combination product.

The combination drug product is currently in post-Phase III development. The wearable drug-device combination product is approximately the size of a hockey puck and is either adhered to the patient using an adhesive patch or is worn near the infusion site. 

“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and president, Phillips-Medisize, in the press release.

Once regulatory approval is achieved, Phillips-Medisize will be contractually obliged to provide commercialization services from its manufacturing site based in Hudson, WI. It is anticipated that the product will launch during the second half of 2020.

Source: Phillips-Medisize